Phase I Safety and Biodistribution Study of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer

Trial Profile

Phase I Safety and Biodistribution Study of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs 124I-PEG AVP 0458 diabody (Primary)
  • Indications Ovarian cancer; Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors Avipep
  • Most Recent Events

    • 21 Apr 2015 New trial record
    • 17 Apr 2015 Status changed from recruiting to completed, according to an Avipep media release.
    • 17 Apr 2015 Results presented at American Association for Cancer Research (AACR) annual meeting, according to an Avipep media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top